Clinicians often face pressure to offer treatment for short stature even when no clear pathologic cause exists. The authors reported a case focusing on growth hormone prescribed for idiopathic short stature and used it to examine competing ethical claims. Beneficence required evaluating potential psychosocial benefit. Non-maleficence required weighing treatment risks and burdens. Respect for autonomy required clear communication with both family and the pediatric patient, while justice raised questions about resource allocation and access. The abstract indicates that the vignette and subsequent discussion illustrate how the four-principle framework can structure conversations and decisions; the abstract does not include specific dosing, outcome metrics, or longitudinal follow-up data.
A second vignette centers on management of precocious puberty in a child with neurodevelopmental delay. The case prompts clinicians to balance expected physiologic harms of untreated early puberty with the child’s capacity to participate in decision making. Authors noted that historical events are invoked to contextualize the dilemma, and the case analysis applies beneficence and non-maleficence to evaluate risks of pharmacologic suppression versus potential psychosocial or medical harms of letting puberty proceed. The abstract does not list precise therapeutic regimens or monitoring protocols; those details may be in the full text but are not reported in the abstract itself.
The third vignette addressed the growing role of diabetes technology in type 1 diabetes management. The authors used a case to interrogate autonomy (adolescent decision-making), beneficence (improving glycemic outcomes), and justice (equitable access to devices and supplies). Data indicated that technology introduces novel ethical tensions: who controls device settings, how to respect adolescent preferences while ensuring safety, and how to respond when families and clinicians disagree about acceptable risk. The abstract frames these as common ethical challenges in everyday practice; it does not provide empirical device-specific outcome data within the abstract.
The fourth vignette focuses on use of glucagon-like peptide 1 receptor agonist therapy for obesity in children. Investigators reported ethical concerns including long-term safety uncertainty, societal stigma, and fairness of access. Beneficence supports offering interventions that reduce obesity-related morbidity; non-maleficence demands attention to unknown long-term effects in developing children. Respect for autonomy requires age-appropriate informed consent processes, and justice requires clinicians to consider how offering or withholding medications may widen disparities. The abstract specifically lists obesity/drug therapy as a MeSH term, but it does not supply drug-specific risk numbers or pediatric approval details in the abstract text.
Across all four cases, the study team observed that applying Beauchamp and Childress’ principles—beneficence, non-maleficence, respect for autonomy, and justice—provided a pragmatic structure for discussion and decision making. The vignettes demonstrate stepwise clinical thinking: identify the biomedical facts, elicit values and preferences from family and child, map benefits and harms, then assess distributive justice implications. The abstract emphasizes the practical nature of the case-based approach. It does not, however, present comparative analyses or quantitative evidence validating one decision pathway over another.
The authors concluded that ethical dilemmas commonly arise in pediatric endocrinology and that routine application of the four principles can be incorporated into clinical care. The abstract situates each vignette within clinical and historical context but stops short of reporting outcome data, formal surveys, or follow-up results. Specific management details—dosing, monitoring intervals, device models, or long-term safety data—are not provided in the abstract and therefore cannot be summarized here. Readers seeking granular therapeutic protocols or empirical outcomes should consult the full text via the journal link provided. Remaining questions include how centers operationalize equity in access, how long-term safety of newer pharmacotherapies in children will be established, and how shared decision-making practices vary across developmental stages—issues the abstract raises but does not resolve.